Trial Profile
A phase II study to determine the efficacy and safety of panitumumab in combination with chemoradiotherapy for unresectable or locally recurrent adenocarcinoma of the rectum with or without metastatic disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2014
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 25 Nov 2006 New trial record.